The FDA has granted orphan drug designation to Birchbiomed’s FS2 as a treatment for idiopathic pulmonary fibrosis, or IPF.

Columnist Samuel Kirton shares his emergency "go bag" checklist of things he brought when he received a bilateral lung ...

Bionews, Inc., the parent company of this site, has partnered with the following nonprofit advocacy organizations to help further the mission of ensuring that patients and caregivers are able to get ...

Researching IPF after her late husband's diagnosis meant learning many new acronyms and abbreviations, says guest writer.

Inhaled lipid nanoparticles loaded with two medicines reduced IPF lung stiffness and fibrosis in mice, outperforming an ...

Pulmonary fibrosis (PF) is a disease of the respiratory system caused by scarring (fibrosis) in the lungs, which makes it harder for patients to breathe. Based on the underlying cause of the scarring, ...

As an organ recipient, columnist Sam Kirton honors donors and their families each year by decorating holiday trees in the ...

Pulmonary fibrosis (PF), as its name suggests, is a disease marked by scarring — or fibrosis — of the lungs, leading to shortness of breath. PF is part of a larger group of more than 200 lung ...

Sam Kirton started his column in November 2021 and writes from his home at Lake Anna, Virginia, where he lives with his wife Susan. His diagnosis at age 59 with idiopathic pulmonary fibrosis in ...

Taking oral dietary supplements of epigallocatechin-3-gallate (EGCG) — an antioxidant in green tea — may stop and reverse the pro-fibrotic (scarring) state of the lungs of people with idiopathic ...

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to BMS-986278, Bristol Myers Squibb’s investigational therapy for progressive pulmonary fibrosis (PF).

Fatigue, sometimes described as overwhelming tiredness or physical malaise, is a common symptom of pulmonary fibrosis (PF) patients. Generally, fatigue is characterized by a lack of energy that does ...